HLB Life Science Receives Approval for Phase 1 Clinical Trial Plan for Refractory Ewing Sarcoma
[Asia Economy Reporter Park Jun-yi] HLB Life Science announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 clinical trial plan of the LSD1 inhibitor (SP-2577) for the treatment of recurrent and refractory Ewing sarcoma patients.
HLB Life Science stated, "We will determine the maximum tolerated dose of SP-2577 in patients with recurrent or refractory Ewing sarcoma and evaluate its safety, tolerability, pharmacokinetic properties, and antitumor activity."
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 50s Arrested for Confining Girlfriend in Car After She Announced Breakup
- Assaulted by Elementary Student During Class... No Protection Due to 'Instructor' Status
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
They also explained, "Through the Phase 1 clinical trial, we expect to gain a competitive advantage in developing targeted therapies for the rare disease Ewing sarcoma."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
